Abstract:Critical scientific questions remain regarding infection with Mycobacterium ulcerans , the organism responsible for the neglected tropical disease, Buruli ulcer (BU). A controlled human infection model has the potential to accelerate our knowledge of the immunological correlates of disease, to test prophylactic interventions and novel therapeutics. Here we present microbiological evidence supporting M . ulcerans JKD8049 as a suitable human challenge strain. This non-genetically modified Australian isolate is susceptible to clinically relevant antibiotics, can be cultured in animal-free and surfactant-free media, can be enumerated for precise dosing, and has stable viability following cryopreservation. Infectious challenge of humans with JKD8049 is anticipated to imitate natural infection, as M . ulcerans JKD8049 is genetically stable following in vitro passage and produces the key virulence factor, mycolactone. Also reported are considerations for the manufacture, storage, and administration of M . ulcerans JKD8049 for controlled human infection. In this paper, we progress our research towards establishing a controlled human infection model (CHIM) of Buruli ulcer, caused by Mycobacterium ulcerans . It is crucial that the challenge agent used for such experiments is thoroughly characterised; not only is this important to ensure standardisation between participants, but also to reinforce their safety. Using established criteria, we systematically demonstrate why the isolate M . ulcerans JKD8049 may be a suitable challenge strain. This strain is non-genetically modified, susceptible to antibiotics, can be cultured in relatively simple media, and can be filtered and preserved as individual bacteria to ensure accurate dosing of participants. Even after repeatedly culturing the organism for months, it remains genetically stable, so significant mutations are not expected to develop during manufacture. After preserving the isolate at -80°C, it can be revived and diluted for human inoculation at very low doses. Importantly, it produces the toxin mycolactone, so it is expected to recreate typical Buruli ulcer disease in participants, which will be important to properly test vaccines and other therapeutics. We also demonstrate a set of principles to ensure the produced batch is free from contamination.

Vaccination efforts for Buruli ulcer

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection

Overview: Mycobacterium ulcerans Disease (Buruli Ulcer)

Structural Basis and Designing of Peptide Vaccine using PE-PGRS Family Protein of Mycobacterium ulcerans – An Integrated Vaccinomics Approach

Burkholderia vaccines: are we moving forward?

Toward better cures for Mycobacterium abscessus lung disease

A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study

Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis

Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model

Tuberculosis: Current state of knowledge: An Epilogue

Perspectives on Development and Advancement of New Tuberculosis Vaccines

Systematic review: Global host range, case fatality and detection rates of Mycobacterium ulcerans in humans and potential environmental sources

Novel Targets for the Development of Tuberculosis Vaccine

An overview of Buruli ulcer in Australia

Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines

Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue?

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

challenge strain selection for a Buruli ulcer controlled human infection model

Mucosal and systemic immune responses to Vibrio cholerae infection and oral cholera vaccines (OCVs) in humans: a systematic review

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis